SUPERNUS PHARMACEUTICALS, INC. — Form 8-K
Filed August 3, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 88/100
What the filing says
Supernus Pharmaceuticals and Indivior announced an all-stock merger of equals on August 3, 2026, expected to close in Q4 2026. The combined company will have ~$2.2B in LTM net revenue (as of 6/30/26) with diversified CNS portfolio including SUBLOCADE (opioid use disorder), Qelbree (ADHD), Zurzuvae (postpartum depression), and Gocovri/Onapgo (Parkinson's). Jack Khattar (Supernus CEO) will lead combined entity; exchange ratio is fixed but specific terms not disclosed in this filing.
Why this rating
Transformational merger creating ~$2.2B revenue platform (130% of Supernus current market cap ~$1.7B), materially expands portfolio and pipeline. Fixed exchange ratio and integration execution risks remain, but scale and diversification are business-changing for Supernus shareholders.
See more from August 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.